BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused ...

BioCryst President and CEO Jon Stonehouse will also address members of the HAE community in attendance in a corporate presentation during the Summit.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) ...

Chief Executive Officer Jon Stonehouse said the addition of these skills and expertise to the leadership team is exactly what we need at this time. In the pre-market trading, BioCryst ...

BioCryst President and CEO Jon Stonehouse will also address members of the HAE community in attendance in a corporate presentation during the Summit. About ORLADEYO® (berotralstat) ...

RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head ...

BioCryst sells European Orladeyo rights to Neopharmed for up to $264 million, plans to eliminate term debt and boost long-term cash position.